Overview

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that will use a challenge with live virus as intervention. Comparison of the clinical observations and laboratory measurements generated in both studies will inform us about the similarities and differences in innate and adaptive immune responses elicited by both types of exposure to influenza virus antigen(s).

Phase:

Phase 4

Details

Lead Sponsor:

University Hospital, Ghent

Collaborators:

CEVAC Core Lab, University Ghent
deCODE genetics, Iceland
Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany
VisMederi srl, Sienna, Italy

Treatments:

Vaccines